Roctavian (valoctocogene roxaparvovec or valoctocogene roxaparvovec-rvox) is a gene therapy that treats severe hemophilia A in adults. This medication can prevent or lower the number of bleeding episodes by helping the body make an important blood-clotting protein. Roctavian (valoctocogene roxaparvovec) is given as a one-time intravenous (IV) infusion through the veins by a healthcare provider. Common side effects of this medication include nausea, tiredness, and infusion-related reactions (e.g., rash and itching).
Hemophilia A is a genetic condition where people have low levels of factor VIII, one of the clotting factors. As a result, they're at higher risk for bleeding.
Roctavian (valoctocogene roxaparvovec) is a type of gene therapy. It uses empty viral vectors to deliver working factor VIII genes into your body. Then, your body uses the genes to make more factor VIII. Having more factor VIII means that your body is better able to stop bleeds.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Tips for before the Roctavian (valoctocogene roxaparvovec) infusion:
Tips for the Roctavian (valoctocogene roxaparvovec) infusion day:
Tips for after the Roctavian (valoctocogene roxaparvovec) infusion:
Roctavian (valoctocogene roxaparvovec) helps your body make more factor VIII proteins, which can lower the risk of excessive bleeding. Studies show that people who received Roctavian (valoctocogene roxaparvovec) had fewer serious bleeding episodes for 3 years after treatment than those who didn't. In addition, most people were able to stay off factor VIII replacement therapy after receiving Roctavian (valoctocogene roxaparvovec). Keep in mind that Roctavian (valoctocogene roxaparvovec) might not be right for everyone. Talk with your provider about the best treatment plan for you.
No, Roctavian (valoctocogene roxaparvovec) isn't a cure for hemophilia A. Currently, all available treatments or medications for hemophilia A only temporarily replace the missing factor VIII (blood clotting factor) so that your blood can clot normally. People with hemophilia A should regularly watch out for bleeding symptoms ranging from nosebleeds, bleeding from the gums to excessive bruising or bleeding after an injury. Make sure to let your provider know if you've an upcoming surgery or dental procedure so they can help you lower your risk of major bleeds.
You should avoid drinking alcohol for at least a year after receiving Roctavian (valoctocogene roxaparvovec). This is Roctavian (valoctocogene roxaparvovec) can cause liver problems, and drinking alcohol can worsen this side effect. Depending on your liver health, your provider will let you know what's a safer amount to drink after the first year.
After you receive Roctavian (valoctocogene roxaparvovec), your provider will order blood tests weekly to check your factor VIII activity levels to see how well the medication is working. At the same time, they'll also check your liver labs to see if you have any liver irritation or damage, which can be a side effect of Roctavian (valoctocogene roxaparvovec). In addition, your provider will check for factor VIII inhibitors, which are antibodies your body might make against factor VIII; these antibodies can prevent this medication from working well. Your provider will also be doing liver ultrasounds yearly to check for symptoms of liver cancer, which is also a possible side effect of Roctavian (valoctocogene roxaparvovec).
Before you receive Roctavian (valoctocogene roxaparvovec), your provider will test your blood for factor VIII inhibitors. These inhibitors are antibodies (proteins) that your immune system makes as a result of using common hemophilia A treatments like factor VIII replacement products. The antibodies block factor VIII from working in your body. Since Roctavian (valoctocogene roxaparvovec) helps your body make more factor VIII, the medication won't work well if you have these inhibitors. Your provider will discuss other options that might work better for you.
Roctavian (valoctocogene roxaparvovec) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Roctavian (valoctocogene roxaparvovec) can cause infusion reactions, such as rash, itching, sneezing, coughing, fever, nausea, diarrhea, and more. Serious reactions like anaphylaxis or closing of the throat are possible as well. Your provider will watch for these reactions during your infusion and for at least 3 hours after you've received Roctavian (valoctocogene roxaparvovec). If you experience any reaction to Roctavian (valoctocogene roxaparvovec) during treatment, tell your provider right away so they can slow or stop your infusion until your symptoms go away. If your symptoms worsen, your provider might give you steroids or antihistamines for symptom relief.
Roctavian (valoctocogene roxaparvovec) can cause liver problems, typically within the first year of treatment. Many people who develop liver problems don't notice symptoms, but do see higher liver enzymes through labs. To check for liver problems, your provider order blood tests weekly after you've received Roctavian (valoctocogene roxaparvovec) for at least the first 6 months. Avoid alcohol for at least a year after infusion to prevent liver damage. If you experience signs and symptoms of liver damage, such as upper right stomach pain, yellowing of the skin or whites of the eyes, or dark urine, talk with your provider immediately.
Based on the way Roctavian (valoctocogene roxaparvovec) works, there's a possible risk of developing liver cancer after treatment. Your risk might be higher if you have a history of liver problems, are older in age, or have a history of long-term alcohol use. For your safety, your provider might order ultrasound screenings and blood tests every year for at least 5 years after treatment to check for cancer. Speak with your provider if you have concerns about the risk of liver cancer. Let your provider know right away if you have symptoms of liver cancer, such as swelling in the belly, yellowing of the skin or whites of the eyes, or confusion.
Rarely, Roctavian (valoctocogene roxaparvovec) can cause serious blood clots since it raises the levels of the blood-clotting protein, factor VIII, in your body. Blood clots can be life-threatening and can happen anywhere in your body. Get medical attention right away if you have any signs or symptoms of a blood clot:
- Brain: weakness or numbness in your arms, legs, or face on one side of the body, trouble speaking, blurry vision, dizziness, loss of balance, trouble walking, or confusion - Eyes: trouble seeing, bulging eye, double vision - Heart: chest pain, sweating, nausea, or dizziness - Lungs: trouble breathing, chest pain, or cough - Legs: cramps, swelling, pain, or muscle tightness
Your risk of getting a blood clot is higher if you have certain heart conditions. Talk with your provider if you have any questions regarding your risk of blood clots.
Each milliliter (mL) of Roctavian (valoctocogene roxaparvovec) contains 2 × 1013 vector copies (vc) of the working factor VIII gene. Your provider will determine the dose of Roctavian (valoctocogene roxaparvovec) based on your body weight.
The typical recommended dose is 3 mL/kg of body weight injected through the veins by a healthcare provider as a one-time infusion.
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Roctavian (valoctocogene roxaparvovec) will not be safe for you to take.